Zai Lab (HKSE:09688) Dividends per Share : HK$0.00 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Dividends per Share?

Zai Lab's dividends per share for the three months ended in Mar. 2024 was HK$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2024 was HK$0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Zai Lab's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Zai Lab Dividends per Share Historical Data

The historical data trend for Zai Lab's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Dividends per Share Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Zai Lab Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Zai Lab's Dividends per Share

For the Biotechnology subindustry, Zai Lab's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zai Lab's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Zai Lab's Dividend Yield % falls into.

Zai Lab Dividends per Share Calculation

Dividends paid to per common share.

Zai Lab (HKSE:09688) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Zai Lab's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.375
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Zai Lab Dividends per Share Related Terms

Thank you for viewing the detailed overview of Zai Lab's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab (HKSE:09688) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

ZLAB:USA ZLAB:Mexico 1ZLB:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Executives

Wellington Management Group Llp	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Janus Henderson Group Plc	2102 Investment manager
Du Ying	2101 Beneficial owner
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Fmr Llc	2201 Interest of corporation controlled by you
Invesco Advisers, Inc.	2102 Investment manager
Invesco Developing Markets Fund	2106 Person having a security interest in shares
Baillie Gifford & Co	2102 Investment manager
Citigroup Inc.	2502 Approved lending agent

Zai Lab (HKSE:09688) Headlines

No Headlines